A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer (Q73269108)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 October 2000

Language	Label	Description	Also known as
English	A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer	scientific article published on 01 October 2000

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

phase II clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pancreatic cancer

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

H Oettle

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

M Arning

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

U Pelzer

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

C Stroszczynski

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J Langrehr

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

P Reitzig

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

M Kindler

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J Herrenberger

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

R Musch

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

E W Korsten

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

D Huhn

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

H Riess

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 October 2000

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1267-1272

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of advanced and metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy in the treatment of cancer of the pancreas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Practical recommendations for the management of adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008364018881

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008364018881

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106115%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73269108&oldid=1967260635"